2.90
+0.11(+3.94%)
Currency In USD
Address
21 Erie Street
Cambridge, MA 02139
United States of America
Phone
617-564-0013
Sector
Healthcare
Industry
Biotechnology
Employees
234
First IPO Date
October 20, 2022
| Name | Title | Pay | Year Born |
| Dr. Keith Michael Gottesdiener M.D., Ph.D. | President, Chief Executive Officer, Secretary & Director | 1.06M | 1954 |
| Dr. Jeremy S. Duffield M.D., Ph.D. | Chief Scientific Officer | 680,650 | 1968 |
| Dr. Ann L. Lee Ph.D. | Chief Technical Officer | 684,782 | 1962 |
| Dr. Andrew Anzalone M.D., Ph.D. | Co-Founder & Head of Prime Editing Platform | 0 | 1987 |
| Dr. Allan Reine M.D. | Chief Financial Officer | 0 | 1975 |
| Ms. Carman Alenson CPA, M.B.A. | Senior Vice President of Finance & Chief Accounting Officer | 0 | 1966 |
| Ms. Niamh Alix | Chief Human Resources Officer | 0 | N/A |
| Dr. Karen Brown J.D., Ph.D. | Senior Vice President of Intellectual Property & Legal Affairs | 0 | N/A |
| Dr. Meredith Goldwasser | Senior Vice President and Head of Strategy & Corporate Operations | 0 | 1971 |
| Dr. David R. Liu Ph.D. | Co-Founder & Member of Scientific Advisory Board | 0 | N/A |
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.